PRELUDE THERAPEUTICS INC Financing Cash Flow
PRELUDE THERAPEUTICS INC (PRLD) reported Financing Cash Flow of $85.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $85.82M, a 231845.95% increase year-over-year.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$314.00K.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $24.94M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$5.00K.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2025 was $24.82M.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2024 was -$120.00K, a 100.09% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2023 was $136.40M, a 16635.58% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC net cash provided by (used in) financing activities for fiscal 2022 was $815.00K, a 99.51% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $85.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $85.51M 10-Q · filed 2026-08-11 | $110.45M derived: sum of 3 quarters · filed 2026-08-11 | $110.44M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$314.00K 10-Q · filed 2026-05-12 | $24.63M derived: sum of 2 quarters · filed 2026-05-12 | $24.63M derived: sum of 3 quarters · filed 2026-05-12 | $24.66M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $24.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $24.94M derived: sum of 2 quarters · filed 2026-03-10 | $24.98M derived: sum of 3 quarters · filed 2026-08-11 | $24.82M 10-K · filed 2026-03-10 | |
| 2025-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $32.00K derived: sum of 2 quarters · filed 2026-08-11 | -$128.00K 10-Q · filed 2025-11-12 | -$162.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$123.00K 10-Q · filed 2026-08-11 | -$157.00K derived: sum of 3 quarters · filed 2026-08-11 | -$288.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$160.00K 10-Q · filed 2026-05-12 | -$194.00K derived: sum of 2 quarters · filed 2026-05-12 | -$325.00K derived: sum of 3 quarters · filed 2026-05-12 | -$266.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$165.00K derived: sum of 2 quarters · filed 2026-03-10 | -$106.00K derived: sum of 3 quarters · filed 2026-03-10 | -$120.00K 10-K · filed 2026-03-10 | |
| 2024-09-30 | -$131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$72.00K derived: sum of 2 quarters · filed 2025-11-12 | -$86.00K 10-Q · filed 2025-11-12 | $25.15M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $45.00K 10-Q · filed 2025-08-14 | $25.28M derived: sum of 3 quarters · filed 2025-08-14 | $25.37M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$14.00K 10-Q · filed 2025-05-06 | $25.22M derived: sum of 2 quarters · filed 2025-05-06 | $25.31M derived: sum of 3 quarters · filed 2025-05-06 | $136.65M derived: sum of 4 quarters · filed 2025-05-06 | |
| 2023-12-31 | $25.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $25.32M derived: sum of 2 quarters · filed 2025-03-10 | $136.66M derived: sum of 3 quarters · filed 2025-03-10 | $136.40M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $111.43M derived: sum of 2 quarters · filed 2024-11-06 | $111.16M 10-Q · filed 2024-11-06 | $111.31M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $111.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $111.07M 10-Q · filed 2024-08-12 | $111.22M derived: sum of 3 quarters · filed 2024-08-12 | $111.37M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$269.00K 10-Q · filed 2024-05-07 | -$114.00K derived: sum of 2 quarters · filed 2024-05-07 | $34.00K derived: sum of 3 quarters · filed 2024-05-07 | -$41.00M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $303.00K derived: sum of 2 quarters · filed 2024-02-15 | -$40.73M derived: sum of 3 quarters · filed 2024-02-15 | $815.00K 10-K · filed 2024-02-15 | |
| 2022-09-30 | $148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$40.89M derived: sum of 2 quarters · filed 2023-11-01 | $660.00K 10-Q · filed 2023-11-01 | $2.61M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | -$41.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $512.00K 10-Q · filed 2023-08-03 | $2.47M derived: sum of 3 quarters · filed 2023-08-03 | $3.18M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $41.55M 10-Q · filed 2023-05-08 | $153.00K 10-Q · filed 2022-05-10 | $43.50M derived: sum of 2 quarters · filed 2023-05-08 | $44.21M derived: sum of 3 quarters · filed 2023-05-08 | $44.63M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.67M derived: sum of 2 quarters · filed 2023-03-15 | $3.09M derived: sum of 3 quarters · filed 2023-03-15 | $164.90M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.13M derived: sum of 2 quarters · filed 2022-11-14 | $162.94M 10-Q · filed 2022-11-14 | $161.64M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $162.23M 10-Q · filed 2022-08-09 | $160.93M derived: sum of 3 quarters · filed 2022-08-09 | $378.68M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $161.81M 10-Q · filed 2022-05-10 | $160.50M derived: sum of 2 quarters · filed 2022-05-10 | $378.26M derived: sum of 3 quarters · filed 2022-05-10 | $378.19M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $216.45M derived: sum of 2 quarters · filed 2022-03-17 | $216.38M derived: sum of 3 quarters · filed 2022-03-17 | $246.23M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $217.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $217.69M derived: sum of 2 quarters · filed 2021-11-12 | $247.53M 10-Q · filed 2021-11-12 | $247.44M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | -$65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $29.78M 10-Q · filed 2021-08-12 | $29.69M derived: sum of 3 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $29.85M 10-Q · filed 2021-05-11 | $29.75M derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $29.73M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $29.82M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |